Subscribe: Market Wire - Pharmaceuticals and Biotech: Biotech
http://img.marketwire.com/rss/mwPBBI.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
announced  clinical  company  development  jan  january  marketwired jan  marketwired january  marketwired  nasdaq  new  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Biotech

Marketwired - Biotech



Marketwired - Biotech



Last Build Date: Sun, 22 Jan 2017 22:04:27 EST

Copyright: Copyright: (C) Marketwired
 



biOasis Provides AGM Update -- Expanding The biOasis Deal Flow Pipeline

Sun, 22 Jan 2017 21:30:00 EST

VANCOUVER, BC--(Marketwired - January 22, 2017) - BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier (BBB), has provided a corporate update in advance of its Annual and Special Meeting of Shareholders to be held at 1780 - 400 Burrard Street, Vancouver, BC, on January 23, 2017 at 10:00 AM, PST.




Prima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference

Sun, 22 Jan 2017 19:00:07 EST

SYDNEY, AUSTRALIA--(Marketwired - Jan 22, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") announces that the submission titled "TACTI-mel, Two ACTive Immunotherapies in Melanoma: Combination of IMP321 (LAG-3Ig) with an Anti-PD-1 Antagonist in a Phase I Trial" has been accepted for a presentation at the 2nd Annual Cancer Immunotherapy Conference, part of 24th International Molecular Medicine Tri-Conference, in San Francisco, California, between February 20 - 22, 2017.




"New to the Street" Broadcasting on Fox Business Network January 22, 2017 @ 1:30 PM ET / 10:30AM PT Featuring XFit Brands, Inc. (XFIT)

Fri, 20 Jan 2017 17:30:20 EST

More "New To The Street" TV to feature Vystar Corp. (VYST) and Accurexa, Inc. (ACXA), February 2017




Servier Appoints MaSTherCell for the Development of its CAR-T Cell Therapy Manufacturing Platform

Fri, 20 Jan 2017 09:00:00 EST

GERMANTOWN, MD--(Marketwired - Jan 20, 2017) -   Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that its wholly-owned subsidiary, MaSTherCell S.A., specializing in the delivery of optimized process industrialization capacities to cell therapy organizations, has signed a master service agreement with Servier for the development of a manufacturing platform for allogeneic cell therapies. Under the master service agreement, MaSTherCell is developing a CAR-T cell therapy manufacturing platform, which will enable industrial and commercial manufacturing of Servier's cell therapy products. This is a critical step in the development of these products for later stage clinical trials.




Rennova Health's Pharmacogenomics Subsidiary Granted Patent

Fri, 20 Jan 2017 08:30:00 EST

WEST PALM BEACH, FL--(Marketwired - January 20, 2017) - Rennova Health, Inc. (NASDAQ: RNVA), (NASDAQ: RNVAZ) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, announced today that its Genomas, Inc. pharmacogenomics subsidiary has been granted a Patent by the US Patent and Trademark Office.




New Xtalks Webinar on Clinical Evaluation Reports (CERs): Global Benefits and The Impact of MEDDEV Updates to Manufacturers

Fri, 20 Jan 2017 07:30:00 EST

During a live broadcast, the speaker will examine the requirements listed in MEDDEV 2.7/1 revision. 4, discuss notable changes from MEDDEV 2.7/1 revision 3, while focusing on the global benefits of the Clinical Evaluation Report for your product's path to market.




Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer

Thu, 19 Jan 2017 18:07:57 EST

SYDNEY, AUSTRALIA--(Marketwired - Jan 19, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced the first patient has been dosed as part of the enlarged randomised phase of its AIPAC Phase IIb clinical trial for IMP321 in metastatic breast cancer.




Lattice Biologics Announces New Private Placement

Thu, 19 Jan 2017 17:31:39 EST

New funding raise of up to US$800,000




IntelGenx Grants Stock Options

Thu, 19 Jan 2017 16:15:00 EST

SAINT-LAURENT, CANADA--(Marketwired - Jan. 19, 2017) - IntelGenx Technologies Corp. ("IntelGenx", or the "Company") (TSX VENTURE:IGX)(OTCQX:IGXT) announced today that the Company's board of directors granted options to acquire a total of 300,000 common shares under the 2016 Stock Option Plan.




Newly Created Standards Coordinating Body Seeks to Advance Development and Establishment of Regenerative Medicine Standards

Thu, 19 Jan 2017 15:23:19 EST

Builds upon call for standards development in 21st Century Cures Act




PBMI Releases Second Pharmacy Trends in Accountable Care Organizations Report

Thu, 19 Jan 2017 13:00:00 EST

PLANO, TX--(Marketwired - Jan 19, 2017) -  The Pharmacy Benefit Management Institute released the second edition of its Pharmacy Trends in Accountable Care Organizations Report today, sponsored by Takeda Pharmaceuticals, U.S.A., Inc. This is the industry's only report exclusively dedicated to exploring pharmacy management trends in the commercial, Medicaid, and Medicare ACO space. The report reflects responses from 141 providers representing 8.3 million patients from across the country.




The Alliance for Regenerative Medicine Launches Standards Coordinating Body to Advance Development and Establishment of Industry-Wide Standards

Thu, 19 Jan 2017 12:22:41 EST

Builds upon call for standards development in 21st Century Cures Act




Capha Pharmaceuticals to Focus on Medical Marijuana Industry Under Leadership of Kyle J. Remenda President & COO

Thu, 19 Jan 2017 10:00:00 EST

WEST KELOWNA, BC--(Marketwired - January 19, 2017) - CAPHA PHARMACEUTICALS INC. ("Capha" and/or the "Company") is pleased to announce that the Company will be focusing on the medical marijuana industry under the leadership of Kyle J. Remenda, the Company's recently appointed President & COO.




Amedica Announces Pricing of Public Offering to Raise $4.5 Million

Thu, 19 Jan 2017 09:46:33 EST

SALT LAKE CITY, UT--(Marketwired - Jan 19, 2017) -  Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride ceramics, today announced the pricing of an underwritten public offering of common stock and warrants with a public offering price of $0.51 for one share of common stock and 0.45 warrants. Each whole warrant is exercisable for one share of common stock. The Company expects to receive gross proceeds of approximately $4.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Company has also granted a 45-day option to the underwriters to purchase up to an additional 15% of the shares of common stock plus up to 15% of the warrants; provided that in no event may the aggregate market value of securities sold in the offering, including from the over-allotment option, exceed the limitations set forth in Rule I.B.6 of Form S-3 solely to cover over-allotments, if any.




Vaxil Bio Expands Into Infectious Diseases With First US Patent for MTbuVax(TM)

Thu, 19 Jan 2017 09:30:00 EST

Receives USPTO Notice of Allowance for MTbuVax(TM) Family of Signal Peptide Vaccines and their use in Treating Major Infectious Diseases




AssistRx Acquires Caret(TM), Providing Users with Cutting Edge Technology to Boost Patient Care Management, Adherence, and Compliance

Thu, 19 Jan 2017 09:01:00 EST

ORLANDO, FL--(Marketwired - Jan 19, 2017) -  AssistRx (ARx), the leading enterprise technology platform focused on simplifying the patient journey for specialty and highly-managed medications, today announces its acquisition of Caret, and Caret's Care Management Platform. Caret provides healthcare providers, specialty pharmacies, patients, and payers a best-in-class communication platform powered by actionable data such as point-of-service decision making, care management programs and near real-time updates on patients. ARx plans to integrate these features into the AssistRx Platform, to enhance the patient journey, drive quality-based healthcare, and improve outcomes.




InMed Pharma Appoints Eli Lilly Finance Executive to Board of Directors -- CFN Media

Thu, 19 Jan 2017 09:00:00 EST

SEATTLE, WA--(Marketwired - Jan 19, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing InMed Pharmaceuticals Inc.'s (OTCQB: IMLFF) (CNSX: IN) recent appointment of Martin Bott to its Board of Directors, the company's existing team, and what it means as InMed progresses towards its first clinical trial in INM-750 for the treatment of Epidermolysis Bullosa as well as the rest of its clinical pipeline.




Lexaria and NeutriSci Announce Successful Cannabinoid Tablet Development and Positive Results From Initial Human Observational Trials

Thu, 19 Jan 2017 08:00:00 EST

KELOWNA, BC--(Marketwired - January 19, 2017) - Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") and NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX VENTURE: NU) (FRANKFURT: 1N9) are pleased to announce the successful development and initial trial of the industry's first zero-sugar cannabinoid / pterostilbene edible tablet utilizing both NeutriSci's and Lexaria's proprietary and patented technologies.




Golden Leaf to Present on Cannabis Investor Webcast on January 26, 2017

Thu, 19 Jan 2017 08:00:00 EST

TORONTO, ON--(Marketwired - January 19, 2017) - Golden Leaf Holdings Ltd. ("GLH" or the "Company") (CSE: GLH) (OTCQB: GLDFF), a leading cannabis oil solutions company built around recognized brands, is pleased to announce that it will be a presenting company on the upcoming Cannabis Investor Webcast. The Webcast is scheduled to take place on Thursday, January 26, and GLH is scheduled to present from 2pm ET to 2:45pm ET.




70% of Global Drug Safety Teams Outsource Case Management Activities

Thu, 19 Jan 2017 07:44:00 EST

RESEARCH TRIANGLE PARK, NC--(Marketwired - January 19, 2017) - Data published by pharmaceutical competitive intelligence firm Cutting Edge Information found that literature services are the most commonly outsourced item among 70% of surveyed pharmacovigilance teams.




Vertical Integration of CRISPR/Cas9 Genome Engineering in Drug Discovery, New Webinar Hosted by Xtalks

Thu, 19 Jan 2017 07:30:00 EST

TORONTO, ON--(Marketwired - January 19, 2017) - Industry expert Dr. Anne-Marie Zuurmond, Associate Director of Genome Engineering, Discovery, Charles River Laboratories will discuss several CRISPR/Cas9 case studies during this webinar covering different aspects of the drug discovery process with an emphasis on the generation of in vitro models for high-throughput screening and the creation of new mouse models of disease.




Moleculin Announces Expanded Scientific Advisory Board

Thu, 19 Jan 2017 07:00:00 EST

HOUSTON, TX--(Marketwired - January 19, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that Drs. Sandra Silberman and Paul Waymack have joined the Company's Scientific Advisory Board (SAB). The Company's current SAB also includes Dr. Waldemar Priebe (Chair) and Dr. Madeleine Duvic.




Optymyze Takes the Gold in Brandon Hall Group's 2016 Excellence in Technology Awards

Thu, 19 Jan 2017 07:00:00 EST

Optymyze Sales Operations is Recognized for Best Advance in Sales Enablement and Performance Tools




Proto Script Pharmaceutical Corp. Building New Partnerships with Independent Practice Associations (IPA)

Thu, 19 Jan 2017 06:00:00 EST

RANCHO CUCAMONGA, CA--(Marketwired - Jan 19, 2017) - Proto Script Pharmaceutical Corp. dba PSP Homecare ("PSP" or the "Company") (OTC PINK: PSCR), a durable medical equipment provider, today provided this update regarding its current business and future expansion plans with Independent Practice Associations.




Applied DNA Sciences to Attend Upcoming Investor Conferences

Thu, 19 Jan 2017 05:30:00 EST

STONY BROOK, NY--(Marketwired - January 19, 2017) - Applied DNA Sciences, Inc. (Applied DNA) (NASDAQ: APDN), a provider of DNA-based supply chain, anti-counterfeiting and anti-theft technology, product genotyping and product authentication solutions, announces its upcoming participation in the following institutional investor conferences in January and February:




Targazyme Inc. Receives Additional U.S Patent Award Designed to Improve Cell Therapy Clinical Efficacy Outcomes

Wed, 18 Jan 2017 16:16:23 EST

CARLSBAD, CA--(Marketwired - January 18, 2017) - Targazyme Inc., a clinical stage biopharmaceutical company developing novel enzyme technologies and products to improve clinical efficacy, safety and cost of care outcomes for patients undergoing cancer immunotherapy, stem cell transplantation and regenerative medicine, announced today that the United States Patent & Trademark Office has awarded Targazyme, Patent 9,511,095 entitled "Cells Treated by In-Vitro Fucosylation and Methods of Production and Use Thereof".




Bio-Rad to Report Fourth-Quarter and Full-Year 2016 Financial Results Thursday, February 23, 2017

Wed, 18 Jan 2017 16:05:00 EST

HERCULES, CA--(Marketwired - Jan 18, 2017) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2016 on Thursday, February 23, 2017, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.




Amedica Announces Proposed Public Offering of Common Stock and Warrants

Wed, 18 Jan 2017 16:01:00 EST

SALT LAKE CITY, UT--(Marketwired - Jan 18, 2017) - Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride ceramics, today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. The common stock and warrants are being offered under the Company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). Net proceeds from the offering will be used by Amedica to (1) remain in compliance with the financial covenants in its outstanding Loan and Security Agreement; (2) support working capital needs and other general corporate purposes; (3) fund research and development and commercialization activities of Amedica's product candidates, including the funding of clinical trials Amedica plans to conduct for its product candidates; and (4) continue to build sales, marketing and distribution capabilities for Amedica's silicon nitride technology platform and other products, including the costs of inventory and instruments.




Departments of Urology and Oncology Approve Protocol for OncBioMune's Phase 2/3 Trial of ProscaVax for Prostate Cancer in Mexico

Wed, 18 Jan 2017 14:50:36 EST

BATON ROUGE, LA--(Marketwired - January 18, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce the receipt of acknowledgement and authorization to perform the protocol proposed for the Phase 2/3 clinical trial of ProscaVax from the Department of Urology of the High Specialty Hospital IMSS Siglo XXI ("HSH IMSS") in Mexico. The clinical study is being sponsored by OncBioMune Mexico S.A. de C.V., a joint venture between the Company and its planned acquisition target, Vitel Laboratorios S.A. de C.V., and being conducted at HSH IMSS, which is considered the foremost government hospital in Mexico.




PHZIO Telehealth Webinar Link

Wed, 18 Jan 2017 13:30:36 EST

CULVER CITY, CA--(Marketwired - Jan 18, 2017) - eWellness Healthcare Corporation, (OTCQB: EWLL) is the first telehealth company for physical therapy to offer insurance reimbursable remotely monitored physical therapy (PT) treatments. The Company successfully held its initial webinar this morning. Please see the following link to view this webinar: https://wnarchives.s3.amazonaws.com/45426582/62c11c14-baa2-4ad7-b8cd-521b38fd3542/archive.mp4. More information about our telehealth solution is available at our PHZIO.COM website: https://www.phzio.com




Brown Technical Media Corp. Announces Uplist to the QB Tier of the OTC Markets

Wed, 18 Jan 2017 10:30:00 EST

HOUSTON, TX--(Marketwired - Jan 18, 2017) - Brown Technical Media Corp., a division of Panther Biotechnology Inc. (OTCQB: PBYA), an e-commerce company building the first full service training and career advancement brand for the skilled trades, is pleased to announce today that it has been accepted for up listing to the OTCQB effective immediately.




Premier Biomedical Pain Management Solutions Announces Product Distribution Agreement of Their Superior Pain Relief Products

Wed, 18 Jan 2017 10:15:00 EST

EL PASO, TX--(Marketwired - Jan 18, 2017) - Premier Biomedical, Inc. (OTCQB: BIEI) announced today their newly created joint venture company, Premier Biomedical Pain Management Solutions, LLC (PBPMS) has signed a distribution agreement contract with the Pain Relief & Wellness Strategy Center in Grove City, Pennsylvania to sell and distribute its pain relief products. Initially, the contract will cover pain relief patches and roll-ons, but will expand as new products are introduced.




EAG Laboratories Adds New Capabilities in Dermal Absorption Testing

Wed, 18 Jan 2017 09:00:00 EST

HERCULES, CA--(Marketwired - Jan 18, 2017) - EAG Laboratories, a global scientific services company that provides testing, analytical and characterization services to technology- and life-science-related industries, announced the addition of dermal absorption studies to its suite of GLP-compliant testing services. The company now offers testing outlined in OECD 427 (in vivo studies in rodent models) and OECD 428 (in vitro studies using human and animal skin), which are often performed in parallel to predict dermal absorption in humans (sometimes called "the triple pack" or "parallelogram" approach).




Predictive Technology Group, Inc. (PRED) Reaches Key Clinical Milestone in Development of Genetic Tests for Infertility and Endometriosis

Wed, 18 Jan 2017 09:00:00 EST

Development of ARTGuide(R) Test Will Rapidly Accelerate Short-Term Company Growth




VPR Brands, LP will be Re-Launching the STINGER at the BIG Industry in Los Angeles California

Wed, 18 Jan 2017 08:30:00 EST

FORT LAUDERDALE, FL--(Marketwired - Jan 18, 2017) - VPR Brands, LP (OTC PINK: VPRB) is proud to announce its participation in the 2017 Big Industry Show in Los Angeles, California on January 19-20th where we will be showcasing our flagship product, the STINGER, part of our Honey Stick Brand.




Biomerica Announces Second Quarter Financial Results; Sales up Over 22% for the Quarter

Wed, 18 Jan 2017 08:19:00 EST

IRVINE, CA--(Marketwired - January 18, 2017) - Biomerica, Inc. (NASDAQ: BMRA) today reported net sales of $1,432,206 for the three months ended November 30, 2016, compared to $1,165,080 for the same period in the previous year, an increase of 22.9%. Net sales were $2,842,317 for the first six months of fiscal 2017 compared to $2,452,073 for the first six months in fiscal 2016, an increase of 15.9%.




Pharma Compliance Teams Approving Physician Compensation Cap Exceptions

Wed, 18 Jan 2017 08:17:00 EST

RESEARCH TRIANGLE PARK, NC--(Marketwired - January 18, 2017) - Although more pharmaceutical companies have instituted compensation limits as a response to scrutiny over their payments to physicians, there are still exceptions to those rules.




NuGene International Initiates Targeted Launch of REVELLUS(TM) Hair Fortifying Serum

Wed, 18 Jan 2017 08:00:00 EST

Newly Improved Formulation Leverages NuGene's Proprietary Stem Cell Technology




Vinergy Resources/MJ Biopharma Appoint Scientific Advisory Board Chair to Pursue Clinical Testing of Cannabinoids for Therapeutics

Wed, 18 Jan 2017 08:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 18, 2017) - Vinergy Resources Ltd. ("Vinergy" or the "Company") (CSE:VIN)(CSE:VIN.CN) in conjunction with its proposed acquisition of MJ Biopharma (announced December 14, 2016) is pleased to announce that it has appointed Dr. William Panenka, MD as Chair of the Company's Scientific Advisory Board (SAB). Bringing on the right human capital through strategic hires is an important part of the Company's strategy to develop, test and identify specific cannabinoid isolates for targeted therapeutic purposes.




Upcoming Webinar on Development by Design: Hovione's Approach to Spray Drying Process Development

Wed, 18 Jan 2017 07:30:00 EST

TORONTO, ON--(Marketwired - January 18, 2017) - On Tuesday, January 31, 2017, Xtalks will host a complimentary webinar featuring Márcio Temtem, Associate Director of Particle Design and Formulation Development at Hovione and João Vicente, Team Leader of Particle Engineering and Solubility Enhancement at Hovione, as the keynote speakers.




MediXall Appoints Dr. Pedro A. Sanchez, D.O., to be its First Medical Director

Wed, 18 Jan 2017 07:30:00 EST

FT. LAUDERDALE, FL--(Marketwired - Jan 18, 2017) - MediXall Group, Inc. (OTCQB: MDXL) is pleased to announce the appointment of its first Medical Director, Dr. Pedro A. Sanchez, D.O. Dr. Sanchez is a graduate of Southeastern College of Osteopathic Medicine in Ft. Lauderdale, Florida, and served his residency at Wellington Regional Medical Center in Wellington, Florida. Dr. Sanchez is Board Certified by the American Osteopathic Board of Family Physicians, and has been a successful family practice physician for over 25 years.




Omni Health, Inc. names Andrey Soloviev as New CEO

Wed, 18 Jan 2017 07:25:04 EST

MIAMI, FL--(Marketwired - Jan 18, 2017) -  Omni Health, Inc., (OTC PINK: OMHE), a pharmaceutical company, announced today the Board of Directors has selected Andrey Soloviev as its new Chief Executive Officer. Mr. Soloviev will take over, effective immediately, for interim CEO, Michael Hawkins, who shall remain the company's interim CFO. 




American Consumers to Manufacturers: It better be 100% what you say it is or we are not buying, especially if it involves child or forced labor

Wed, 18 Jan 2017 05:30:00 EST

Applied DNA Sciences cotton survey conducted by Harris Poll reveals 30% of consumers say they would stop purchasing a brand if they made a false product claim about their bedding/clothing product; three in five Americans would not purchase if child or forced laborers were involved




Prima BioMed to Maintain NASDAQ Listing

Wed, 18 Jan 2017 02:02:58 EST

SYDNEY, AUSTRALIA--(Marketwired - Jan 18, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) the "Company" has received notification from the Listing Qualifications Department of the NASDAQ Stock Market indicating that the Company's American Depositary Shares have maintained a closing bid price of US$1.00 per share or greater for 10 consecutive business days from 28 December 2016 to 11 January 2017. Accordingly, the Company has regained compliance with NASDAQ Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule") and the Company's American Depositary Shares will remain listed on the NASDAQ Global Market.




Theratechnologies inc. : Les résultats de l'étude pivot de phase III pour l'ibalizumab acceptés pour une présentation de dernière minute dans le cadre du Congrès médical CROI 2017

Tue, 17 Jan 2017 19:15:57 EST

MONTRÉAL, QUÉBEC--(Marketwired - 17 jan. 2017) - Theratechnologies Inc. (Theratechnologies) (TSX:TH) annonce qu'un résumé, soumis par son partenaire, TaiMed Biologics, Inc., des résultats obtenus après 24 semaines de traitement avec l'ibalizumab dans le cadre de l'étude de phase III (TMB-301) a été sélectionné pour une présentation de dernière minute le mardi 14 février 2017 au Conference on Retroviruses and Opportunistic Infections (CROI) qui se tiendra à Seattle, Washington, du 13 au 16 février 2017. Ces résultats ont déjà été annoncés dans un communiqué de presse diffusé le 10 novembre 2016. Dre Brinda Emu, professeure adjoint de médecine, maladies infectieuses, Faculté de médicine de l'université Yale au Connecticut, présentera des données supplémentaires quant à l'efficacité et à l'innocuité en lien avec l'étude de 24 semaines.




Theratechnologies Inc.: Ibalizumab 24-Week Pivotal Phase III Study Results Accepted as a Late Breaker Will Be Presented at CROI 2017

Tue, 17 Jan 2017 19:12:27 EST

MONTREAL, QUEBEC--(Marketwired - Jan. 17, 2017) - Theratechnologies Inc. (Theratechnologies) (TSX:TH) announces that the abstract submitted by its partner, TaiMed Biologics, Inc., for the 24-week study results of the ibalizumab (IBA) phase III study (TMB-301) has been selected for a late breaker presentation, Tuesday, February 14th, 2017, at the Conference on Retroviruses and Opportunistic Infections (CROI) to be held in Seattle, WA, from February 13 to 16, 2017. These results were first announced in our press release of November 10, 2016. Dr. Brinda Emu, Assistant Professor of Medicine, Infectious Diseases, Yale School of Medicine, CT, will be presenting additional efficacy and safety data related to the 24-week study.




Helix BioPharma Corp. Announces Voting Results from Its Annual and Special Meeting of Shareholders

Tue, 17 Jan 2017 17:05:00 EST

TORONTO, ONTARIO--(Marketwired - Jan. 17, 2017) - Helix BioPharma Corp. (TSX:HBP) (FRANKFURT:HBP) ("Helix"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced today the results of matters voted on at its annual and special meeting of shareholders held on January 17, 2017 (the "Meeting").




FPS Pharma Changes Name to Capha Pharmaceuticals Inc.

Tue, 17 Jan 2017 11:10:05 EST

Kyle J. Remenda Appointed President & COO




Medifirst Solutions to Present Its Time Machine Laser in Morocco and Dubai

Tue, 17 Jan 2017 11:00:00 EST

FREEHOLD, NJ--(Marketwired - Jan 17, 2017) - MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the "Company" or "Medifirst") would like to update shareholders regarding its previous announcement about international sales for its FDA cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device.




Health Advance Announces the Closing of the Acquisition of Hantian Labs

Tue, 17 Jan 2017 10:45:10 EST

LAS VEGAS, NV--(Marketwired - Jan 17, 2017) -  Health Advance Inc. (the "Company") (OTC PINK: HADV) is pleased to announce that the Company has closed the Share Exchange Agreement ("Agreement") to acquire Hantian Labs Limited, a private UK corporation (Hereinafter referred to as "Hantian"). As a result of the acquisition, Health Advance will also control 99% of JT Hantian LLC representing the revenue arm of Hantian. Pursuant to the Agreement, the Company has issued 18,000,000 common shares of the Company to the shareholders of Hantian Labs representing the purchase price of Hantian. Accordingly, the Company's issued and outstanding number of common shares increased from 26,520,000 shares to 44,520,000 shares. In addition, Company has waived Hantian's undertaking to raise a minimum financing of $250,000 for marketing of Hantian's product line prior to closing.




Tufts Clinical and Translational Science Institute and Baim Institute for Clinical Research Announce Partnership

Tue, 17 Jan 2017 10:10:00 EST

Students, Faculty, Researchers, and Patients to Benefit from New Collaboration




Pegasystems Advances Pega Product Composer System for Health Insurers to Offer More Personalized Plans and Optimal Customer Experience

Tue, 17 Jan 2017 10:00:00 EST

With Pega PCS, improved data access allows insurers to bring new products to market faster while enabling better collaboration and transparency




Intergraph CAESAR II(R) webinar January 26th to demonstrate how to select appropriate supports in piping design

Tue, 17 Jan 2017 10:00:00 EST

HOUSTON, TX--(Marketwired - Jan 17, 2017) - Intergraph is hosting a CAESAR II webinar on January 26, 2017 at 10:00 a.m. CST / 5:00 p.m. CET (Amsterdam) that will demonstrate how to select from the different types of pipe support components to ensure the best results when modeling piping systems. Proper selection can help prevent future problems such as shutdowns and repairs due to an inadequate support component. The webinar will cover a range of supports available in CAESAR II including spring hangers, constant spring hangers, rod hangers, riser clamps, clamps on shoes, and snubbers and struts with dynamic clamps. The webinar leader will be Perwez Shaikh, P.E., vice president of Lisega Oil and Gas Division at its new facility in Houston, Texas.




Advantis Corp. Boosts Bottom Line, Reduces Debt

Tue, 17 Jan 2017 09:26:00 EST

NEWPORT BEACH, CA--(Marketwired - Jan 17, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) announced that it has settled into its new commercial space to meet surging demand of Amstercan, rosin presses, and other products. The company has also announced that it has reduced debt by $250,000.




GeoVax to Collaborate with Georgia State University on Development of Therapeutic Hepatitis B Vaccine

Tue, 17 Jan 2017 09:00:00 EST

Targeting Chronic Hepatitis B Infections Affecting More Than 240 Million People Worldwide




Common Heart Drug Repurposed to Treat Rare Cancer in Europe

Tue, 17 Jan 2017 09:00:00 EST

Orphan Drug Designation Confirms Propranolol's Treatment Benefits




PHZIO Telehealth Clinic Orientation and On-boarding

Tue, 17 Jan 2017 09:00:00 EST

CULVER CITY, CA--(Marketwired - Jan 17, 2017) - eWellness Healthcare Corporation, (OTCQB: EWLL) is the first telehealth company for physical therapy to offer insurance reimbursable remotely monitored physical therapy (PT) treatments. The Company is pleased to announce that it has begun clinic orientation and on-boarding of selected PT's at Motion PT Group and our other previously announced PT clinic licensees. More information about our telehealth solution is available at our PHZIO.COM website: https://www.phzio.com




Advanced Proteome Therapeutics Corporation Announces Issuance of U.S. Patent Covering Novel Molecules for the Treatment of Cancer

Tue, 17 Jan 2017 09:00:00 EST

VANCOUVER, BC--(Marketwired - January 17, 2017) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce issuance of APC's U.S. Patent Application 14/400,190 titled "Site-Specific Labeling and Targeted Delivery of Proteins for the Treatment of Cancer".




Critical Outcome Technologies to Be a Panelist and Presenter at Cantech Investment Conference in Toronto

Tue, 17 Jan 2017 08:30:00 EST

LONDON, ON and BOSTON, MA--(Marketwired - January 17, 2017) - Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company") a clinical stage biotechnology company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that it will be a panelist and presenter at the 2017 Cantech Investment Conference on January 18th at the Metro Toronto Convention Centre.




Pharmaceutical Key Account Managers Favor Hospital System Accounts

Tue, 17 Jan 2017 08:17:00 EST

RESEARCH TRIANGLE PARK, NC--(Marketwired - January 17, 2017) - The majority of surveyed pharmaceutical key account manager (KAM) groups are most likely to support hospital system accounts (88%) and regional/local-level government payers (76%), according to recent data published by competitive intelligence provider Cutting Edge Information.




Glue Named Top 20 New York Ad Agency

Tue, 17 Jan 2017 08:00:00 EST

NEW YORK, NY--(Marketwired - Jan 17, 2017) - Glue Advertising was recently recognized as one of the top 20 advertising agencies in New York. Expertise.com ranked just under 2,000 agencies in the city on 25 variables, across 5 categories, and distinguished Glue for its quality of customer service.




XOR-Labs adds experienced medical device executive Steven Plymale to Board of Directors

Tue, 17 Jan 2017 08:00:00 EST

TORONTO, ON--(Marketwired - January 17, 2017) - XOR-Labs Toronto Inc. (XOR), a spin-off from Toronto General Hospital at University Health Network the world's leading center for lung transplantation and a MaRS Innovation company, today announced the appointment of Steven Plymale as an Independent Director to its Board. Mr. Plymale is the President and COO of Profound Medical, (TSX VENTURE: PRN), an emerging medical device company that is commercializing a real time MR image guided thermal ultrasound ablation treatment for prostate disease. Mr. Plymale has a strong track record of building medical technologies from the critical early stages of product development through operational scale-up and clinical and regulatory pathway development. With this addition, XOR continues to add independent oversight, diversity, and expertise.




Ritter Pharmaceuticals Appoints William Merino, Ph.D., to its Board of Directors

Tue, 17 Jan 2017 08:00:00 EST

LOS ANGELES, CA--(Marketwired - Jan 17, 2017) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced it has appointed William Merino, Ph.D., to its Board of Directors. Dr. Merino will occupy a newly-created seat, advising on regulatory, clinical and related strategies.




Beyond the Smoke Stacks: Texas Ropes in $4 Billion Pharma-Bio Investment, an Industrial Info News Alert

Tue, 17 Jan 2017 07:30:00 EST

SUGAR LAND, TX--(Marketwired - Jan 17, 2017) - Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- When many people hear the word "Texas," it evokes a number of clichés, typically a mélange of cattle, chemical plants, oil and gas drilling, and rodeos. But that sells the state short, for beyond the smoke stacks of the hundreds of the state's chemical processing plants and refineries are a surprising number of life-science manufacturing plants and research centers.




Corbus Pharmaceuticals Receives Orphan Designation for JBT-101 for the Treatment of Systemic Sclerosis in the European Union

Tue, 17 Jan 2017 07:30:00 EST

NORWOOD, MA--(Marketwired - January 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the European Commission has granted Orphan Designation in the European Union ("EU") for the Company's novel synthetic oral endocannabinoid-mimetic drug, JBT-101 ("Resunab") for the treatment of systemic sclerosis.




Study Shows Improved Primary Adherence as high as 99% using InstyMeds Automated Direct-to-Patient Dispensers

Tue, 17 Jan 2017 07:00:00 EST

MINNEAPOLIS, MN--(Marketwired - Jan 17, 2017) - A 2017 study conducted at the University of Minnesota and published in the journal ClinicoEconomics and Outcomes Research found patients that have their medications dispensed at the point of care have much higher rates of adherence.




Evotec and MaRS Innovation Establish Strategic Partnership to Launch Fibrocor Therapeutics

Tue, 17 Jan 2017 07:00:00 EST

TORONTO, ON and HAMBURG, GERMANY--(Marketwired - January 17, 2017) - Evotec AG (FRANKFURT: EVT) (TecDAX, ISIN: DE0005664809) and MaRS Innovation today announced the launch of Fibrocor Therapeutics LP ("Fibrocor"), a Toronto-based company focused on developing first-in-class therapeutics targeting fibrotic diseases. The company was launched with CDN $ 2.8 m (approx. $ 2.1 m) financing, which includes cash from MaRS Innovation. Evotec will provide all drug discovery activities and will also receive an equity stake.




Proto Script Pharmaceutical Corp. discusses Opportunities in the Expanding US Power Wheelchair and Mobility Scooter Market

Tue, 17 Jan 2017 06:00:00 EST

RANCHO CUCAMONGA, CA--(Marketwired - Jan 17, 2017) - Proto Script Pharmaceutical Corp. dba PSP Homecare ("PSP" or the "Company") (OTC PINK: PSCR), a durable medical equipment provider, is pleased to provide this discussion regarding opportunities in the expanding US power wheelchair and mobility scooter market.




Cytovance(R) Biologics announces Michael O'Mara as Senior Vice President of Manufacturing Operations

Tue, 17 Jan 2017 06:00:00 EST

OKLAHOMA CITY, OK--(Marketwired - January 17, 2017) - Cytovance® Biologics, Inc., a leading full service biopharmaceutical contract manufacture of mammalian and microbial biologics, today announced the addition of Mike O'Mara as Sr. Vice President of Manufacturing Operations.




Rennova Health Completes Asset Purchase Agreement of Scott County Community Hospital

Tue, 17 Jan 2017 06:00:00 EST

WEST PALM BEACH, FL--(Marketwired - January 17, 2017) - Rennova Health, Inc. (NASDAQ: RNVA) (NASDAQ: RNVAZ) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, announced today that it has closed the previously reported Asset Purchase Agreement to acquire certain assets related to Scott County Community Hospital, based in Oneida, Tennessee ("Scott County Hospital").




Phoseon Technology se lance sur le marché de la biologie

Tue, 17 Jan 2017 00:00:00 EST

Nouvel accent et nouvelles possibilités pour la technologie LED brevetée




Phoseon Technology steigt in den Life-Sciences-Markt ein

Tue, 17 Jan 2017 00:00:00 EST

Neuer Schwerpunkt und neue Möglichkeiten für patentierte LED-Technologie




Phoseon Technology Enters Life Sciences Market

Tue, 17 Jan 2017 00:00:00 EST

New focus and capabilities for patented LED Technology




Intergraph(R) CADWorx(R) & Analysis Solutions

Mon, 16 Jan 2017 15:43:56 EST

Intergraph(R) PV Elite(R) webinar January 24th to discuss updates in API 579 corrosion analyses code for pressure vessel design




FPS Pharma Changes Name to Capha Pharmaceuticals Inc.

Mon, 16 Jan 2017 13:39:12 EST

Kyle J. Remenda Appointed President & COO




SpeeDx and UgenTec launch FastFinder for ResistancePlus MG Test

Mon, 16 Jan 2017 10:03:46 EST

Artificially intelligent interpretation module automatically incorporates test results into lab information systems




Health Advance Inc. Announces the Closing of the Acquisition of Hantian Labs

Mon, 16 Jan 2017 09:00:00 EST

LAS VEGAS, NV--(Marketwired - Jan 16, 2017) - Health Advance Inc. (the "Company") (OTC PINK: HADV) is pleased to announce that the Company has closed the Share Exchange Agreement ("Agreement") to acquire Hantian Labs Limited, a private UK corporation (Hereinafter referred to as "Hantian"). As a result of the acquisition, Health Advance will also control 99% of JT Hantian LLC representing the revenue arm of Hantian. Pursuant to the Agreement, the Company has issued 18,000,000 common shares of the Company to the shareholders of Hantian Labs representing the purchase price of Hantian. Accordingly, the Company's issued and outstanding number of common shares increased from 26,520,000 shares to 44,520,000 shares. In addition, Company has waived Hantian's undertaking to raise a minimum financing of $250,000 for marketing of Hantian's product line prior to closing.




Bio-Rad to Acquire RainDance Technologies and Droplet Intellectual Property

Mon, 16 Jan 2017 08:30:00 EST

HERCULES, CA--(Marketwired - Jan 16, 2017) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, announced today that it has entered into a definitive agreement to purchase RainDance Technologies, Inc. The terms of the acquisition were not disclosed. Bio-Rad expects the transaction to close during the first quarter of 2017. The company will discuss the acquisition further during Bio-Rad's upcoming fourth-quarter and full-year 2016 financial results conference call. 




Hutchison China Meditech Limited: Change of Directors

Mon, 16 Jan 2017 06:29:00 EST

HONG KONG, CHINA--(Marketwired - Jan 16, 2017) - Hutchison China Meditech Limited (NASDAQ: HCM) (AIM: HCM)




Hutchison China Meditech Limited: Fruquintinib Phase I/II Clinical Data at ASCO GI

Mon, 16 Jan 2017 03:45:17 EST

HONG KONG, CHINA--(Marketwired - Jan 16, 2017) - Hutchison China Meditech Limited (NASDAQ: HCM) (AIM: HCM)




Hutchison China Meditech Limited: Sulfatinib Phase II Study in 2nd Line BTC in China

Mon, 16 Jan 2017 03:18:16 EST

HONG KONG, CHINA--(Marketwired - Jan 16, 2017) - Hutchison China Meditech Limited (NASDAQ: HCM) (AIM: HCM)




Hutchison China Meditech Limited: Fruquintinib Combination Study in 1st-Line NSCLC

Mon, 16 Jan 2017 03:02:43 EST

HONG KONG, CHINA--(Marketwired - Jan 16, 2017) - Hutchison China Meditech Limited (NASDAQ: HCM) (AIM: HCM)